Fubei Biopharmaceutical Technology

Fubei Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for neurodegenerative diseases. Founded by world-class neuroscientists, the company focuses on high-unmet-need conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Frontotemporal Dementia. Fubei Bio leverages a proprietary drug discovery platform that combines deep biological insights with advanced screening technologies to target neuro-inflammation and protein homeostasis. Its lead candidate, FB-1001, is a small molecule targeting the Sortilin 1 pathway to increase Progranulin levels, currently in clinical development. Headquartered in Hangzhou, China, the company is supported by leading venture capital firms and aims to transform the landscape of CNS therapeutics.